It can directly bind EGFR, decrease its phosphorylation and subsequently inhibit the expression of its downstream target lysyl oxidase (LOX), leading to reduced migration of non-small cell lung cancer (NSCLC) cells. This evidence concerns the gene EGFR and non-small cell lung carcinoma.